Stop calling it billing: Revenue cycle is where value is won or lost in healthcare roll-ups

By Michael Needham

In buy-and-build healthcare strategies, revenue often scales faster than revenue integrity. But with each acquisition, variability in billing, coding, and collections compounds, eroding margins, slowing cash conversion, and introducing risk at exit.

In many sponsor-backed platforms, Revenue Cycle Management (RCM) is still treated as a back-office function – something to “tidy up” after the core integration work is done. The board deck may show revenue growth, but often beneath the surface, denial rates vary dramatically by site, net collection rates fluctuate, DSO creeps upward, and aged AR accumulates. Leaving RCM until late in the integration process is costing healthcare roll-ups margin, delaying millions in cash, and putting pressure on valuation multiples at exit.

This gap creates a significant and often overlooked opportunity: treating Revenue Cycle Management (RCM) as a core lever in converting revenue into cash and high-quality earnings.

Case study: The hidden EBITDA in denials

In one PE-backed multi-state physician platform, leadership initially attributed margin pressure to payer mix.

However, a deeper RCM diagnostic told a different story. Three outsourced billing vendors were operating under percentage-of-collections contracts. Denial rates ranged from 6% to 18% across practices, with no consistent root-cause reporting, and DSO varied by more than 20 days between sites. The issue was not market-driven; it was entirely structural.

By consolidating vendors, centralized KPI baselining, and standardizing denial analytics, the platform improved net collection rates by more than two percentage points, reduced DSO by 11 days, and expanded EBITDA by approximately 180 basis points. During this time, no new providers, service lines, or pricing changes were introduced; impact was driven purely by revenue discipline.

What may look like scaling is often just aggregation. Without a deliberate designing of processes, incentives, and performance, variability compounds and control over revenue lapses. The question is why this opportunity to capture value is so often unclaimed.

Where value leakage becomes structural

The answer often lies in how revenue cycle activities are commercially structured. As platforms scale through acquisition, vendor models, processes, and incentives are inherited alongside operations and rarely standardized early enough. For instance, many roll-ups retain billing vendor contracts, leaving them untouched to avoid operational disruption. Those contracts frequently use percentage-of-collections pricing. On the surface, sponsor-vendor incentives appear aligned; in practice, they are not. Vendors are not directly incentivized to reduce preventable denials, eliminate rework, or improve revenue consistency.

Addressing this requires more than operational improvement; it requires restructuring how those activities are commercially governed and incentivized. At one PE-backed platform, Procurement negotiated vendor agreements to introduce clean claim rate thresholds, denial reduction performance metrics, transparent root-cause reporting, and enterprise pricing leverage. This commercial restructuring alone improved EBITDA before any operational changes were implemented.

Cash is the multiplier most sponsors underestimate

The impact of strong RCM extends beyond EBITDA improvements.

In a behavioral health roll-up, DSO had quietly reached nearly 70 days. Aged AR over 120 days was approaching one-fifth of receivables. The business was “profitable”, but it was not liquid. After centralizing eligibility verification, standardizing pre-authorizations, and consolidating billing workflows, DSO was reduced by 16 days. Working capital release exceeded $6 million. This liquidity funded additional acquisitions without incremental equity.

In leveraged platforms, revenue cycle integration is often the fastest way to accelerate IRR – not by growing EBITDA, but by accelerating cash. Sponsors who focus exclusively on margin expansion are underutilizing one of the most powerful levers in the model.

Earnings quality is tested at exit

All of this is tested at exit. In diligence, buyers look beyond headline growth to assess how reliably that growth converts into cash. They focus on consistency: how net collection rates compare across sites, how much of receivables sit beyond 120 days, how stable denial trends are, and whether reporting and revenue recognition are standardized. Fragmented revenue cycles create earnings quality anxiety.

In one exit process, standardizing the revenue cycle reduced quality-of-earnings adjustments and supported a stronger valuation outcome, showing that revenue cycle integration does more than just expand EBITDA. It protects it. This is why the sequencing of integration matters.

Reordering integration priorities

Healthcare buy-and-build strategies traditionally start with acquisition, centralizing corporate functions, and standardizing operations before finally addressing the revenue cycle. However, by that point, revenue variability has compounded, cash inefficiency has limited acquisition velocity, and contract misalignment is already embedded.

The sequence should be reversed: revenue cycle integration should begin in diligence and accelerate immediately post-close. RCM is not clerical work. It is enterprise risk management, working capital strategy, and EBITDA integrity. 

The bottom line 

Healthcare buy-and-build is entering a more disciplined era. Reimbursement pressure is real. Labor cost inflation is persistent. Growth is harder to manufacture. In this environment, the way sponsors treat Revenue Cycle Management will become a key performance differentiator. 

Scale without revenue discipline is just aggregation. Integration is what turns revenue into cash and equity value.